Eli Lilly and Company (NYSE:LLY) to Issue Quarterly Dividend of $1.73

Eli Lilly and Company (NYSE:LLY) announced a quarterly dividend on Monday, December 8th. Shareholders of record on Friday, February 13th will be given a dividend of 1.73 per share on Tuesday, March 10th. This represents a c) annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a 15.3% increase from Eli Lilly and Company’s previous quarterly dividend of $1.50.

Eli Lilly and Company has raised its dividend payment by an average of 0.2%annually over the last three years and has raised its dividend every year for the last 11 years. Eli Lilly and Company has a payout ratio of 20.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Eli Lilly and Company to earn $31.12 per share next year, which means the company should continue to be able to cover its $6.00 annual dividend with an expected future payout ratio of 19.3%.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $995.63 on Tuesday. The stock has a market capitalization of $941.25 billion, a price-to-earnings ratio of 48.71, a PEG ratio of 1.12 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The firm’s 50 day simple moving average is $924.25 and its 200-day simple moving average is $812.32. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the previous year, the business posted $1.18 EPS. The business’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in Eli Lilly and Company in the second quarter valued at $27,000. Vermillion & White Wealth Management Group LLC boosted its stake in Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after buying an additional 16 shares during the period. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $29,000. Finally, Steph & Co. lifted its holdings in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.